Profile
Christi Shaw is the Executive Chairperson of Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases. In this role, she helps guide Kyverna's strategic direction and governance as the company develops KYV-101, an autologous CD19 CAR T-cell program, and KYV-201, an allogeneic CAR T-cell program.
| Role | Insider |
|---|
| Notability | 40/100 |
|---|
Board memberships
- Kyverna Therapeutics, Inc.
Awards & honors
- Led corporate strategy and governance as Executive Chairperson of Kyverna Therapeutics
- Oversaw development of KYV-101 and KYV-201 CAR T programs for autoimmune diseases
Frequently Asked Questions
Who is Shaw Christi?
Christi Shaw is the Executive Chairperson of Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases. In this role, she helps guide Kyverna's strategic direction and governance as the company develops KYV-101, an autologous CD19 CAR T-cell program, and KYV-201, an allogeneic CAR T-cell program.…
How many SEC Form 4 filings has Shaw Christi submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Shaw Christi's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.